Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Advanced High Grade Neuroendocrine Tumors
NCT00004922Phase 2
Key facts
- Status
- Completed
- Start
- Jun 1999
- Primary completion
- Jun 2002
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Drugs
- irinotecan
- Conditions
- Neuroendocrine Neoplasm (NEN)
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in Neuroendocrine Neoplasm (NEN), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Objective Response Rate, Time to Tumor Progression and 2 more. Started Jun 1999; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Irinotecan
Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks.
03
Who it enrols
Adults with metastatic or unresectable high grade neuroendocrine tumors, measurable disease, adequate organ function, and no more than 2 prior chemotherapy regimens.
04
Endpoints
Primary
Objective Response Rate
Time to Tumor Progression
Overall Survival
Adverse Events
Beyond the preview
Go deeper on NCT00004922.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004922.